Back to Journals » OncoTargets and Therapy » Volume 9

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Total article views   Abstract views HTML views PDF downloads Totals
5,540 Dovepress* 3,938 792+ 821 4,730
PubMed Central* 0 810 341 810
Totals 3,938 1,602 1,162 5,540
*Since 4 August 2016
+Since July 2016

View citations on PubMed Central and Google Scholar